Wickenstones and WittKieffer recently co-hosted a roundtable with industry experts to discuss how the Inflation Reduction Act (IRA) and Joint Clinical Assessment (JCA) will impact the pharmaceutical industry.
Central to this discussion was the recognition that incoming legislation will challenge current organizational structures by increasing overall evidence demands and reshaping decision-making for development plans. Despite acknowledging these changes, the pharmaceutical industry appears underprepared and unclear on how best to adapt.
In this extended read, we evaluate the challenges presented by the IRA and JCA and recommend ways to reshape these structures to maximize asset potential.
